448 related articles for article (PubMed ID: 20027153)
21. Transintestinal transport mechanisms of 5-aminosalicylic acid (in situ rat intestine perfusion, Caco-2 cells) and Biopharmaceutics Classification System.
Smetanová L; Stětinová V; Kholová D; Kuneš M; Nobilis M; Svoboda Z; Květina J
Gen Physiol Biophys; 2013 Sep; 32(3):361-9. PubMed ID: 23846255
[TBL] [Abstract][Full Text] [Related]
22. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis.
Roger E; Lagarce F; Garcion E; Benoit JP
J Control Release; 2009 Dec; 140(2):174-81. PubMed ID: 19699246
[TBL] [Abstract][Full Text] [Related]
23. [Transport mechanism of swertiamain metabolite across Caco-2 model].
Tang C; Zhang Y; Zhang T; Tian C; Liu C
Zhongguo Zhong Yao Za Zhi; 2009 Sep; 34(17):2258-60. PubMed ID: 19943498
[TBL] [Abstract][Full Text] [Related]
24. Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells.
Zhou S; Feng X; Kestell P; Paxton JW; Baguley BC; Chan E
Eur J Pharm Sci; 2005 Apr; 24(5):513-24. PubMed ID: 15784341
[TBL] [Abstract][Full Text] [Related]
25. The effect of conjugated linoleic acid on transepithelial calcium transport and mediators of paracellular permeability in human intestinal-like Caco-2 cells.
Jewell C; Cusack S; Cashman KD
Prostaglandins Leukot Essent Fatty Acids; 2005 Mar; 72(3):163-71. PubMed ID: 15664300
[TBL] [Abstract][Full Text] [Related]
26. Transport of leuprolide across rat intestine, rabbit intestine and Caco-2 cell monolayer.
Guo J; Ping Q; Jiang G; Dong J; Qi S; Feng L; Li Z; Li C
Int J Pharm; 2004 Jul; 278(2):415-22. PubMed ID: 15196645
[TBL] [Abstract][Full Text] [Related]
27. Intestinal permeability of sesquiterpenes in the caco-2 cell monolayer model.
Wu Q; Zhao B; Yang XW; Xu W; Zhang P; Zou L; Zhang LX
Planta Med; 2010 Mar; 76(4):319-24. PubMed ID: 19830652
[TBL] [Abstract][Full Text] [Related]
28. Intestinal transport of bis(12)-hupyridone in Caco-2 cells and its improved permeability by the surfactant Brij-35.
Yu H; Hu YQ; Ip FC; Zuo Z; Han YF; Ip NY
Biopharm Drug Dispos; 2011 Apr; 32(3):140-50. PubMed ID: 21271607
[TBL] [Abstract][Full Text] [Related]
29. Development of simulated intestinal fluids containing nutrients as transport media in the Caco-2 cell culture model: assessment of cell viability, monolayer integrity and transport of a poorly aqueous soluble drug and a substrate of efflux mechanisms.
Lind ML; Jacobsen J; Holm R; Müllertz A
Eur J Pharm Sci; 2007 Dec; 32(4-5):261-70. PubMed ID: 17890067
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of cocktail approach to standardise Caco-2 permeability experiments.
Koljonen M; Hakala KS; Ahtola-Sätilä T; Laitinen L; Kostiainen R; Kotiaho T; Kaukonen AM; Hirvonen J
Eur J Pharm Biopharm; 2006 Nov; 64(3):379-87. PubMed ID: 16914297
[TBL] [Abstract][Full Text] [Related]
31. Role of 99mTc-mannitol and 99mTc-PEG in the assessment of paracellular integrity of cell monolayers.
Shah PJ; Jogani VV; Mishra P; Mishra AK; Bagchi T; Misra AR
Nucl Med Commun; 2007 Aug; 28(8):653-9. PubMed ID: 17625388
[TBL] [Abstract][Full Text] [Related]
32. Intestinal absorption of miltefosine: contribution of passive paracellular transport.
Ménez C; Buyse M; Dugave C; Farinotti R; Barratt G
Pharm Res; 2007 Mar; 24(3):546-54. PubMed ID: 17252190
[TBL] [Abstract][Full Text] [Related]
33. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers.
Ingels F; Beck B; Oth M; Augustijns P
Int J Pharm; 2004 Apr; 274(1-2):221-32. PubMed ID: 15072798
[TBL] [Abstract][Full Text] [Related]
34. Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase: comparative studies using in vitro, in situ and in vivo models.
Sun H; Bi H; Huang M; Liu D; Qin Z
Biopharm Drug Dispos; 2010 Nov; 31(8-9):486-94. PubMed ID: 20936649
[TBL] [Abstract][Full Text] [Related]
35. [Transport and metabolism of daidzein in Caco-2 cell model].
Ge YB; Ma Y; Li WZ
Zhong Yao Cai; 2009 Oct; 32(10):1563-7. PubMed ID: 20112722
[TBL] [Abstract][Full Text] [Related]
36. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
[TBL] [Abstract][Full Text] [Related]
37. Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa.
Miret S; Abrahamse L; de Groene EM
J Biomol Screen; 2004 Oct; 9(7):598-606. PubMed ID: 15475479
[TBL] [Abstract][Full Text] [Related]
38. The absorptive flux of the anti-epileptic drug substance vigabatrin is carrier-mediated across Caco-2 cell monolayers.
Nøhr MK; Hansen SH; Brodin B; Holm R; Nielsen CU
Eur J Pharm Sci; 2014 Jan; 51():1-10. PubMed ID: 24008184
[TBL] [Abstract][Full Text] [Related]
39. Transport properties of puerarin and effect of Radix Angelicae Dahuricae extract on the transport of puerarin in Caco-2 cell model.
Liang XL; Zhao LJ; Liao ZG; Zhao GW; Zhang J; Chao YC; Yang M; Yin RL
J Ethnopharmacol; 2012 Dec; 144(3):677-82. PubMed ID: 23085309
[TBL] [Abstract][Full Text] [Related]
40. Functional characterization of peptide transporters in MDCKII-MDR1 cell line as a model for oral absorption studies.
Agarwal S; Jain R; Pal D; Mitra AK
Int J Pharm; 2007 Mar; 332(1-2):147-52. PubMed ID: 17097248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
